Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis

Abstract

Despite the success of antiretroviral therapy (ART), people living with HIV (PLWH) are still at higher risk for cardiovascular diseases (CVDs) that are mediated by chronic inflammation. Identification of novel inflammatory mediators with the inherent potential to be used as CVD biomarkers and also as therapeutic targets is critically needed for better risk stratification and disease management in PLWH. Here, we investigated the expression and potential role of the multi-isoform proinflammatory cytokine IL-32 in subclinical atherosclerosis in PLWH (n=49 with subclinical atherosclerosis and n=30 without) and HIV- controls (n=25 with subclinical atherosclerosis and n=24 without). While expression of all tested IL-32 isoforms (α, β, γ, D, ϵ, and θ) was significantly higher in peripheral blood from PLWH compared to HIV- controls, IL-32D and IL-32θ isoforms were further upregulated in HIV+ individuals with coronary artery atherosclerosis compared to their counterparts without. Upregulation of these two isoforms was associated with increased plasma levels of IL-18 and IL-1β and downregulation of the atheroprotective protein TRAIL, which together composed a unique atherosclerotic inflammatory signature specific for PLWH compared to HIV- controls. Logistic regression analysis demonstrated that modulation of these inflammatory variables was independent of age, smoking, and statin treatment. Furthermore, our in vitro functional data linked IL-32 to macrophage activation and production of IL-18 and downregulation of TRAIL, a mechanism previously shown to be associated with impaired cholesterol metabolism and atherosclerosis. Finally, increased expression of IL-32 isoforms in PLWH with subclinical atherosclerosis was associated with altered gut microbiome (increased pathogenic bacteria; Rothia and Eggerthella species) and lower abundance of the gut metabolite short-chain fatty acid (SCFA) caproic acid, measured in fecal samples from the study participants. Importantly, caproic acid diminished the production of IL-32, IL-18, and IL-1β in human PBMCs in response to bacterial LPS stimulation. In conclusion, our studies identified an HIV-specific atherosclerotic inflammatory signature including specific IL-32 isoforms, which is regulated by the SCFA caproic acid and that may lead to new potential therapies to prevent CVD in ART-treated PLWH.

Clinical and Metabolomic Effects of Lactiplantibacillus plantarum and Pediococcus acidilactici in Fructose Intolerant Patients

“…De Preter et al [49] reported a higher value of hexanoic acid in a control group compared with patients with Inflammatory Bowel Disease. Hexanoic acid also exerted a potential positive role as immune system modulator in the regulation of Interleukin-32, an important cytokine involved in inflammation and cancer development [50]. These data are also in line with our findings, which reported a negative correlation between hexanoic acid and the worsening of gastrointestinal clinical symptoms.…”

The Protective Effect of Sulforaphane on Dextran Sulfate Sodium-Induced Colitis Depends on Gut Microbial and Nrf2-Related Mechanism

“…It is reported that the contents of propionic acid, butyric acid, iso-butyric acid, and valeric acid evidently decreased in the colonic contents in DSS-induced colitis mice, which is quite consistent with our results ( 36 ). Caproic acid shows anti-inflammatory effect for its reduction in NF-κB transactivation and decrease in inflammatory cytokine production ( 37 , 38 ). More importantly, fecal levels of caproic acid have been shown to inversely correlate with Crohn's disease activity ( 39 ).…”

Th17 CD4+ T-Cell as a Preferential Target for HIV Reservoirs

“…Cells in inflamed gut tissue are described as having a 27-fold higher frequency of HIV DNA than cells in non-inflamed gut tissue (110). This immune activation and inflammation is thought to lead to an increase in the frequency of other conditions such as metabolic and cardiovascular diseases (111).…”